ANL

Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on the research and development of innovative cancer therapies, primarily targeting opportunities in the United States and Mainland China. Headquartered in Grand Cayman, the firm is committed to leveraging cutting-edge scientific methodologies to meet significant unmet medical needs in oncology. With a strong and diverse pipeline, Adlai Nortye is strategically positioned to make a meaningful impact in the cancer treatment landscape, paving the way for potential collaborations and partnerships within the biopharmaceutical industry.